Mortality Comparison of Using Anti Interleukin-6 Therapy and Using Standard Treatment in Severe Covid-19

Jonathan Christianto Sutadji, Agung Dwi Wahyu Widodo, Danti Nur Indiastuti

= http://dx.doi.org/10.20473/fmi.v57i2.21929
Abstract views = 407 times | downloads = 129 times

Abstract


Severe Coronavirus Disease 19 (COVID-19) can cause serious lung inflammation and death. COVID-19 is characterized by a high mortality rate. This severity is associated with the overproduction of proinflammatory cytokines called "cytokine storms". One of the cytokines that play a central role is Interleukin-6 (IL-6). High IL-6 levels are associated with mortality. Expectedly, the IL-6 blockade could reduce cytokine storms and thus reduce deaths in severe COVID-19 patients. This systematic review aimed to summarize the comparison between mortality using anti-IL-6 therapy and mortality using standard treatment in severe COVID-19 patients. We systematically searched the PubMed, ScienceDirect, and ProQuest databases until 13 August 2020. After screening, twelve studies matched the inclusion criteria. The mortality of the anti-IL-6 therapy group was lower than the standard treatment group without anti-IL-6 therapy in COVID-19 patients in 10 of the 12 studies obtained. Four of the ten studies statistically found a significant difference in mortality of the anti-IL-6 therapy group and the standard treatment group. Confirmation of anti-IL-6 therapy effectiveness in reducing mortality in severe COVID-19 patients will require randomized controlled trials.

Full Text:

PDF

References


Antwi-Amoabeng D, Kanji Z, Ford B et al (2020). Clinical outcomes in covid-19 patients treated with tocilizumab: An individual patient data systematic review. Journal of Medical Virology. Available from https://onlinelibrary.wiley.com/doi/10.1002/jmv.26038. Accessed August 12, 2020

Canziani LM, Trovati S, Brunetta E, et al (2020). Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Journal of autoimmunity 114, 1-7.

Capra R, De Rossi N, Mattioli F, et al (2020). Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. European Journal of Internal Medicine 76, 31-35.

CDC (2020). Coronavirus disease 2019 (COVID-19): Symptoms. centers for disease control and prevention. Available from https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed August 12, 2020

Coperchini F, Chiovato L, Croce L, et al (2020). The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Reviews 53, 25-32.

De Rossi N, Scarpazza C, Filippini C, et al (2020). Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. E-clinical Medicine 25, 1-9.

Ge H, Wang X, Yuan X, et al (2020). The epidemiology and clinical information about COVID-19. European Journal of Clinical Microbiology & Infectious Diseases 39, 1011-1019.

Guaraldi G, Meschiari M, Cozzi-Lepri A, et al (2020). Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology 2, e474-e484.

Klopfenstein T, Zayet S, Lohse A, et al (2020). Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. International Journal of Infectious Diseases 99, 491-495.

Klopfenstein T, Zayet S, Lohse A, et al (2020). Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Medecine et Maladies Infectieuses 50, 397-400.

Li X, Geng M, Peng Y, et al (2020). Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis 10, 102-108.

Liu B, Li M, Zhou Z, et al (2020). Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. Journal of Autoimmunity 111, 1-9.

Luo P, Liu Y, Qiu L, et al (2020). Tocilizumab treatment in COVID-19: A single center experience. Journal of Medical Virology 92, 814-818.

Moore JB, June CH (2020). Cytokine release syndrome in severe COVID-19. Science 368, 473-474.

Rojas-Marte G, Khalid M, Mukhtar O, et al (2020). Outcomes in patients with severe COVID-19 disease treated with tocilizumab: A case-controlled study. QJM 113, 546-550.

Tufan A, Avano─člu GA, Matucci-Cerinic M (2020). Covid-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turkish Journal of Medical Sciences 50, 620-632.

Zhou F, Yu T, Du R, et al (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395, 1054-1062.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Jonathan Christianto Sutadji, Agung Dwi Wahyu Widodo, Danti Nur Indiastuti

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Indexed By

View My Stats

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.